Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center

home / authors / hope-s-rugo-md-helen-diller-family-comprehensive-cancer-center

Articles

Tiffany Traina, MD

Guideline Recommendations for CIN Prophylaxis

Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center
October 22nd 2021

Current recommendations by the National Comprehensive Cancer Network on chemotherapy-induced neutropenia prophylaxis, with special considerations for managing patients with cancer during COVID-19.

Read More

Management of HR+ mBC: Key Prognostic Factors

Management of HR+ mBC: Key Prognostic Factors

Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center;Aditya Bardia, MD, MPH, Massachusetts General Hospital;Dejan Juric, MD, Massachusetts General Hospital;Nicholas McAndrew, MD, MSCE, UCLA Health;Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center
June 30th 2021

Considerations for approaching the treatment of HR-positive metastatic breast cancer through insights on key prognostic factors.

Read More

Role of Molecular Profiling in HR+ Metastatic Breast Cancer

Role of Molecular Profiling in HR+ Metastatic Breast Cancer

Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center;Aditya Bardia, MD, MPH, Massachusetts General Hospital;Dejan Juric, MD, Massachusetts General Hospital;Nicholas McAndrew, MD, MSCE, UCLA Health;Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center
June 30th 2021

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, discuss when it is appropriate to order molecular testing and the impact of testing on the treatment of HR-positive metastatic breast cancer.

Read More

Latest Updated Articles

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer